Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome

Background: This analysis aimed to evaluate the impact of rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome (ACS) and to determine whether therapeutic drug monitoring might provide additional information regarding rivaroxaban do...

Full description

Bibliographic Details
Main Authors:	Liping Zhang, Xiaoyu Yan, Partha Nandy, Stefan Willmann, Keith A. A. Fox, Scott D. Berkowitz, Amarnath Sharma, Anne Hermanowski-Vosatka, Stephan Schmidt, Jeffrey I. Weitz, Dirk Garmann, Gary Peters
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-07-01
Series:	Therapeutic Advances in Cardiovascular Disease
Online Access:	https://doi.org/10.1177/1753944719863641

Similar Items

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
by: Alexander Solms, et al.
Published: (2019-11-01)

Potential role of rivaroxaban in patients with acute coronary syndrome
by: Fitchett DH
Published: (2012-11-01)

The Role of Rivaroxaban in the Treatment of Patients with Stable Coronary Artery Disease
by: O. V. Averkov
Published: (2019-10-01)

NOVEL APPROACH TO ANTITHROMBOTIC TREATMENT OF ACUTE CORONARY PATIENTS WITH RIVAROXABAN
by: I. N. Bokarev, et al.
Published: (2015-07-01)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
by: Jan Beyer-Westendorf, et al.
Published: (2019-04-01)

RIVAROXABAN IN LONG-TERM PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: S. V. Shalaev
Published: (2017-12-01)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
by: Dagmar eKubitza, et al.
Published: (2013-11-01)

Resolution of Extensive Coronary Thrombosis under Rivaroxaban Treatment
by: Murat Yuksel, et al.
Published: (2015-12-01)

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
by: George C. Leef, et al.
Published: (2017-11-01)

Intracranial hemorrhage in patient treated with rivaroxaban
by: Michelle Molina, et al.
Published: (2014-03-01)

Analysis of Effectiveness, Safety, and Bleeding Related to Rivaroxaban in Elderly Patients
by: Huimin Hou MS, et al.
Published: (2020-05-01)

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Coronary Endarterectomy: A Cross Sectional Study
by: Foroud Shahbazi, et al.
Published: (2023-09-01)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial
by: Alex C. Spyropoulos, et al.
Published: (2022-07-01)

APPLICATION OF RIVAROXABAN IN ACUTE CORONARY SYNDROME: EVIDENCE AND CURRENT GUIDELINES
by: O. V. Averkov
Published: (2016-01-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

THE SPECIFICS OF PRESCRIBING TRIPLE ANTITROMBOTIC THERAPY WITH RIVAROXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AFTER CORONARY ARTERY STENTING
by: N. A. Novikova, et al.
Published: (2017-05-01)

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice
by: Shivu GN, et al.
Published: (2014-05-01)

Laboratory monitoring of rivaroxaban in Chinese patients with deep venous thrombosis: a preliminary study
by: Ying Li, et al.
Published: (2020-05-01)

Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial
by: Zhong Yuan, et al.
Published: (2024-04-01)

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation
by: Paul Y. Kim, et al.
Published: (2018-04-01)

Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease
by: N. V. Pogosova, et al.
Published: (2019-12-01)

Update on Rivaroxaban
by: Osama Moussa, et al.
Published: (2010-01-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01)

The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis
by: Nina Haagenrud Schultz, et al.
Published: (2020-01-01)

RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01)

Atrial fibrillation in elderly patients. Features of using rivaroxaban
by: A. D. Erlikh
Published: (2020-06-01)

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis
by: Chan, Kevin E., et al.
Published: (2016)

Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy
by: Chen W, et al.
Published: (2017-03-01)

Intravenous Thrombolysis in a Stroke Patient Receiving Rivaroxaban
by: Felix Fluri, et al.
Published: (2013-10-01)

Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease
by: Stefan Willmann, et al.
Published: (2022-08-01)

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis
by: Mitsuru Ishii, et al.
Published: (2022-11-01)

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness
by: Gary E. Raskob, et al.
Published: (2022-10-01)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
by: Chao‐Lun Lai, et al.
Published: (2017-04-01)

Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
by: Jiaming (Calvin) Liang, MD, MSc, et al.
Published: (2021-10-01)

Rivaroxaban concentrations in acute stroke patients with different dosage forms.
by: Shinichi Wada, et al.
Published: (2019-01-01)

Rivaroxaban: Drug review
by: Abhishek Kumar Singh, et al.
Published: (2020-01-01)

Rivaroxaban in atrial fibrillation
by: Giorgi MA, et al.
Published: (2012-08-01)

SUMMARY OF CONCLUSIONS FROM A CONSENSUS PANEL OF EXPERTS ON THE IMPORTANCE OF RIVAROXABAN IN THE MANAGEMENT OF PATIENTS RECOVERING FROM ACUTE CORONARY SYNDROME
by: M. Ya. Ruda, et al.
Published: (2015-12-01)

Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
by: Shalin Rawal, et al.
Published: (2022-06-01)

Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome
by: Krohn-Grimberghe M, et al.
Published: (2014-05-01)